SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02).

• Portfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217
• Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
• Dosing Commenced in Expanded Phase 2 Program for SAGE-547 in Moderate and Severe Postpartum Depression
• Phase 2 Initiations Planned for SAGE-217 in Essential Tremor and Postpartum Depression in 2H 2016
• Proof-of-Concept Study Initiations Planned with SAGE-547 in Major Depressive Disorder and SAGE-217 in Parkinson’s Disease in 2H 2016

Cash, cash equivalents and marketable securities as of June 30, 2016 were $272.3 million, compared with $186.8 million at December 31, 2015.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.